Enhanced JunD/RSK3 signalling due to loss of BRD4/FOXD3/miR-548d-3p axis determines BET inhibition resistance

Fang Tai; Kunxiang Gong; Kai Song; Yanling He; Jian Shi

doi:10.1038/s41467-019-14083-4

Nature Communications (Jan 2020)

Enhanced JunD/RSK3 signalling due to loss of BRD4/FOXD3/miR-548d-3p axis determines BET inhibition resistance

Fang Tai,
Kunxiang Gong,
Kai Song,
Yanling He,
Jian Shi

Affiliations

Fang Tai: Department of Pathology, Nanfang Hospital, Southern Medical University
Kunxiang Gong: Department of Pathology, Nanfang Hospital, Southern Medical University
Kai Song: Department of Pathology, Nanfang Hospital, Southern Medical University
Yanling He: Department of Pathology, Nanfang Hospital, Southern Medical University
Jian Shi: Department of Pathology, Nanfang Hospital, Southern Medical University

DOI: https://doi.org/10.1038/s41467-019-14083-4
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 16

Abstract

Read online

The clinical use of BET inhibitors (BETi) is limited by primary and acquired resistance. Here, the authors report that BETi resistance is determined by JunD/RSK3 signalling activation induced by the loss of BRD4/Foxd3/miR-548d-3p, which can be reverted by targeting the EGFR-MEK-ERK pathway.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal